ANTX - AN2 Therapeutics, Inc.

QQQ $ 451.64 $ -1.83 (-0.4 %)

DIA $ 399.14 $ -0.07 (-0.02 %)

SPY $ 528.49 $ -1.29 (-0.24 %)

TLT $ 92.06 $ -0.04 (-0.04 %)

GLD $ 220.06 $ -0.83 (-0.38 %)

Previous Close

$ 2.27

Open

$ 2.32

Bid

$ 2.26 x 400

Ask

$ 0.00 x 0

Day's Range

$ 2.25 - $ 2.32

52 Week Range

$ 2.20 - $ 22.22

Volume

241,609

Average Volume

Market Cap

67.56M

Beta (5Y Monthly)

$ 1.60

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-14-2024	03-31-2024	10-Q
2	03-29-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-10-2023	06-30-2023	10-Q
5	05-11-2023	03-31-2023	10-Q
6	03-29-2023	12-31-2022	10-K
7	11-09-2022	09-30-2022	10-Q
8	08-11-2022	06-30-2022	10-Q
9	05-10-2022	03-31-2022	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Evercore ISI Group Maintains In-Line on AN...
05/16/2024 15:51:38

Evercore ISI Group analyst Liisa Bayko maintains AN2 Therapeutics (NASDAQ:ANTX) with a In-Line and lowers the price target f...

12-health-care-stocks-moving-in-thursdays-after-market-session

12 Health Care Stocks Moving In Thursday's...
04/04/2024 20:31:22

JMP Securities Upgrades AN2 Therapeutics t...
04/02/2024 18:05:44

JMP Securities analyst Roy Buchanan upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Market Outperform and ann...

Oppenheimer Reiterates Perform on AN2 Ther...
04/01/2024 13:13:18

Oppenheimer analyst Jeff Jones reiterates AN2 Therapeutics (NASDAQ:ANTX) from Perform to Perform.

AN2 Therapeutics Q4 EPS $(0.57) Beats $(0....
03/28/2024 20:49:43

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0....

ZoomInfo Technologies To Rally Around 50%?...
02/13/2024 13:08:24

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Leerink Partners Downgrades AN2 Therapeuti...
02/13/2024 12:40:35

Leerink Partners analyst Joseph Schwartz downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to Market Perform and low...

Nasdaq Edges Lower; ContextLogic Shares Surge
02/12/2024 19:15:26

U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow...

Why Big Lots Shares Are Trading Lower By A...
02/12/2024 18:07:28

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarte...

Evercore ISI Group Downgrades AN2 Therapeu...
02/12/2024 17:54:03

Evercore ISI Group analyst Liisa Bayko downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to In-Line and lowers the p...

12-health-care-stocks-moving-in-mondays-intraday-session

12 Health Care Stocks Moving In Monday's I...
02/12/2024 17:31:18

dow-surges-over-150-points-gilead-sciences-to-acquire-cymabay-therapeutics-for-43b

Dow Surges Over 150 Points; Gilead Science...
02/12/2024 17:30:46

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded u...

Oppenheimer Downgrades AN2 Therapeutics to...
02/12/2024 16:54:47

Oppenheimer analyst Jeff Jones downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to Perform.

JMP Securities Downgrades AN2 Therapeutics...
02/12/2024 16:52:13

JMP Securities analyst Roy Buchanan downgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Outperform to Market Perform.

US Stocks Mixed; Trimble Issues Weak Outlook
02/12/2024 14:51:40

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 20 points on Monday. Following the market openi...

why-is-infectious-disease-focused-an2-therapeutics-stock-sinking-today

Why Is Infectious Disease-Focused AN2 Ther...
02/12/2024 14:08:38

AN2 Therapeutics pauses Phase 3 enrollment for epetraborole trial in Mycobacterium Avium Complex lung disease. Updates expected...

Monday.com Reports Q4 Results, Joins AN2 T...
02/12/2024 13:16:25

U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 45 points on Monday. Shares of monda...

12-health-care-stocks-moving-in-mondays-pre-market-session

12 Health Care Stocks Moving In Monday's P...
02/12/2024 13:05:59

$an2-therapeutics-to-voluntarily-pause-enrollment-in-phase-3-part-of-phase-23-pivotal-clinical-trial-evaluating-epetraborole-for-treatment-refractory-mycobacterium-avium-complex-mac-lung-disease$

AN2 Therapeutics to Voluntarily Pause Enro...
02/12/2024 11:46:20

AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chr...

JMP Securities Initiates Coverage On AN2 T...
01/04/2024 10:03:29

JMP Securities analyst Roy Buchanan initiates coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform rating and...